Risperidone-d4 – 500 µg

Brand:
Cayman
CAS:
1020719-76-9
Storage:
-20
UN-No:
De Minimis - 2811 / 6.1

Risperidone-d5 is intended for use as an internal standard for the quantification of risperidone (Item No. 13629) by GC- or LC-MS. Risperidone is an atypical antipsychotic that binds to dopamine D2 receptors (Ki = 3 nM) and the serotonin (5-HT) receptor subtype 5-HT2A (Ki = 0.12 nM).{39942,21347} It also binds to dopamine D4, α1- and α2-adrenergic, 5-HT1C, 5-HT1D, and histamine H1 receptors (Kis = 7, 0.81, 7.3, 47, 52, and 2.1 nM, respectively). Risperidone (0.1 mg/kg per day, i.p.) attenuates deficits in prepulse inhibition of the acoustic startle response, but not deficits in social interaction, in a rat neonatal ventral hippocampal lesion model of schizophrenia.{39941} Formulations containing risperidone have been used in the treatment of schizophrenia and bipolar disorder.  

 

Available on backorder

SKU: 10010570 - 500 µg Category:

Description

An internal standard for the quantification of risperidone by GC- or LC-MS


Formal name: 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl-1,1,2,2-d4]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one

Synonyms: 

Molecular weight: 414.5

CAS: 1020719-76-9

Purity: ≥99% deuterated forms (d1-d4)

Formulation: A solid


Application|Mass Spectrometry||Product Type|Biochemicals|Analytical Standards||Product Type|Biochemicals|Isotopically Labeled Standards|Deuterium||Product Type|Biochemicals|Receptor Pharmacology||Research Area|Neuroscience|Behavioral Neuroscience|Bipolar Disorder||Research Area|Neuroscience|Behavioral Neuroscience|Schizophrenia & Psychosis